Sanofi earmarks €1B for new insulin production factory in Beijing news2024-12-02T19:00:06+00:00December 2nd, 2024|Endpoints News|
Exclusive: Athena Countouriotis’ Avenzo taps Shanghai biotech for ADC, adds new fundsnews2024-11-18T12:00:27+00:00November 18th, 2024|Endpoints News|
BeiGene rebrands as BeOne Medicines, dropping name’s link to Chinanews2024-11-14T15:05:14+00:00November 14th, 2024|Endpoints News|
Merck buys into PD-1/VEGF space as Summit comes for Keytrudanews2024-11-14T12:29:52+00:00November 14th, 2024|Endpoints News|
BioNTech buys out partner Biotheus for PD-L1/VEGF cancer drugnews2024-11-13T11:45:55+00:00November 13th, 2024|Endpoints News|
AstraZeneca CEO reaffirms commitment to China following executive’s detentionnews2024-11-12T20:43:03+00:00November 12th, 2024|Endpoints News|
Merck KGaA plans China submission after late-stage win for tumor drugnews2024-11-12T16:09:12+00:00November 12th, 2024|Endpoints News|
Pfizer to invest $1B in China over next five years — reportsnews2024-11-07T20:13:39+00:00November 7th, 2024|Endpoints News|
Senior AstraZeneca exec detained in China amid wider investigationnews2024-11-07T19:54:33+00:00November 7th, 2024|Endpoints News|
Joe Jimenez’s latest Aditum company lines up T cell engager from Chinanews2024-11-07T12:03:51+00:00November 7th, 2024|Endpoints News|
